Pages that link to "Q35930608"

The following pages link to Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer (Q35930608):

Displaying 12 items.

• Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer (Q36544024) (← links)
• Tamoxifen Action in ER-Negative Breast Cancer (Q36688302) (← links)
• Oestrogen receptor negativity in breast cancer: a cause or consequence? (Q37529397) (← links)
• Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer (Q37536680) (← links)
• SIN3A and SIN3B differentially regulate breast cancer metastasis (Q37684611) (← links)
• Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations (Q39135505) (← links)
• Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells (Q47114871) (← links)
• The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. (Q52670829) (← links)
• Hyperuricemia Induces Wnt5a/Ror2 Gene Expression, Epithelial-Mesenchymal Transition, and Kidney Tubular Injury in Mice. (Q55303642) (← links)
• Co-repressor, co-activator and general transcription factor: the many faces of the Sin3 histone deacetylase (HDAC) complex (Q60301962) (← links)
• Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin (Q89536719) (← links)
• New drugs are not enough‑drug repositioning in oncology: An update (Q89989620) (← links)